SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 274 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,563,742 | -54.0% | 133,224 | -41.3% | 0.00% | -50.0% |
| Q1 2024 | $7,744,062 | +104.7% | 227,032 | +73.7% | 0.00% | +100.0% |
| Q4 2023 | $3,783,355 | -40.5% | 130,731 | -43.3% | 0.00% | -50.0% |
| Q3 2023 | $6,357,421 | -26.6% | 230,592 | -20.0% | 0.00% | -33.3% |
| Q2 2023 | $8,666,478 | +55924.8% | 288,306 | -32.5% | 0.00% | -50.0% |
| Q1 2023 | $15,469 | +3.5% | 426,980 | +1.9% | 0.01% | 0.0% |
| Q4 2022 | $14,942 | -99.9% | 418,895 | +12.2% | 0.01% | +20.0% |
| Q3 2022 | $12,643,000 | +23.3% | 373,509 | +5.3% | 0.01% | +25.0% |
| Q2 2022 | $10,254,000 | -36.0% | 354,559 | -31.1% | 0.00% | -20.0% |
| Q1 2022 | $16,034,000 | -23.9% | 514,392 | -32.0% | 0.01% | -16.7% |
| Q4 2021 | $21,057,000 | +2.0% | 756,631 | +0.0% | 0.01% | 0.0% |
| Q3 2021 | $20,635,000 | +43.8% | 756,432 | +62.3% | 0.01% | +50.0% |
| Q2 2021 | $14,351,000 | +87.0% | 466,073 | +59.0% | 0.00% | +100.0% |
| Q1 2021 | $7,676,000 | +4.4% | 293,198 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $7,356,000 | +19.0% | 292,374 | -1.5% | 0.00% | 0.0% |
| Q3 2020 | $6,183,000 | -20.8% | 296,690 | -9.8% | 0.00% | -33.3% |
| Q2 2020 | $7,809,000 | +37.4% | 328,797 | +4.1% | 0.00% | 0.0% |
| Q1 2020 | $5,682,000 | -20.0% | 315,854 | +5.5% | 0.00% | 0.0% |
| Q4 2019 | $7,103,000 | -59.3% | 299,423 | -52.8% | 0.00% | -57.1% |
| Q3 2019 | $17,436,000 | +69.6% | 634,491 | +104.3% | 0.01% | +75.0% |
| Q2 2019 | $10,278,000 | +2347.1% | 310,612 | +2491.0% | 0.00% | +100.0% |
| Q1 2019 | $420,000 | +64.7% | 11,988 | +56.3% | 0.00% | 0.0% |
| Q4 2018 | $255,000 | -62.4% | 7,669 | -43.0% | 0.00% | -50.0% |
| Q3 2018 | $678,000 | -60.2% | 13,465 | -52.7% | 0.00% | -63.6% |
| Q2 2018 | $1,704,000 | +73.7% | 28,464 | +32.9% | 0.01% | +83.3% |
| Q1 2018 | $981,000 | +54.7% | 21,413 | -14.7% | 0.01% | +100.0% |
| Q4 2016 | $634,000 | – | 25,105 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |